00:00We have at our disposal a new way, which is to be able to use these devices for low-tech glucose monitoring in patients in insulin therapy,
00:15also in monosubstantiation, also in those who do less than three substantiations a day.
00:27It is an epochal step, because it gives us the opportunity to monitor the patient's glycemic profile in a sort of daily procedure,
00:45for the whole day and not in an instantaneous way, and in a weekly and weekly model, depending on the type of sensor.
00:55From a patient's point of view, it is fundamental, because it changes, but there is a need for a clinical motivation that explains the risk of hypoglycemia for the use of these devices.
01:15In patients in insulin therapy, we expect that it will certainly improve the progress of the disease.
01:23It is a generational change, because in many cases, especially in the peripheries of the territory,
01:30often and willingly the non-use of these devices still leads to the traditional use of the glycemic diary, which is outdated.
01:41Currently, with these devices, we can better redefine the objectives of care and, consequently, make a better, more appropriate therapy.
01:52The other really innovative aspect is the opening, for which I thank Dr. Messurati, the Association of Patients in the Linear Figure of Lemona,
02:05and Professor Nicola Napoli, President of SID.
02:09I thank for the opening of type 2 diabetes, for the use of these devices in type 2 patients,
02:17who have a high risk of cardiovascular disease and are in therapy with glyphosate and or analogues of GLP1 receptor agonists.
02:24This is an epochal change, because it gives us the opportunity to verify, to improve the educational process
02:33and to make the patient aware of the state of the disease.
02:38In that period, that is, a month, the patient can verify how the glycemic profile changes in relation to what he does,
02:50both from a physical point of view and from the point of view of the nutrients he eats.
02:55These are advantages, I repeat, that are tangible both in the course of the day or in the period of measurement on the glycemic profile,
03:08because they allow us to verify if there is a trend of hyperglycemia in the morning, or pre-prandial, or post-prandial, or at night,
03:18and therefore to immediately correct the patient's physical condition in insulin therapy.
03:25For others, it gives us an increased awareness of the state of the disease,
03:31but above all, I expect, in the long term, an advantage in terms of glycate and in terms of reduction of acute cardiovascular complications,
03:42which are often caused by hypoglycemic spike or nadir states, or even in terms of chronic complications.
03:51And finally, think for the most fragile patients, in some conditions, how useful they can be for the gatekeepers.
Comments